Market Access Insights
Access the relevant market access data and insights you need on health plans, policy restrictions, PBMs, providers, and more
Report
May 3, 2010
Formulary Advantages Among Hepatitis C Virus Therapies: Pharmacy directors do not yet understand the pharmacoeconomic incentives to cover emerging therapies
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Increasing diagnosis and treatment rates, and substantial unmet need combine to make HCV a high-gr…
